![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Department of Pharmacological Sciences (L.S., P.G., U.G., C.B., V.C., M.B., E.G., E.N., A.G., E.T.), Centre for Excellence on Neurodegenerative Diseases (L.S., E.G., E.T.), Proteomic and Protein Structure Study Group (E.G.), University of Milan, Milan, Italy; MG Consulting Company (M.d.G.), Rossemaison, Switzerland; and Monzino Cardiologic Centre IRCCS (C.F., M.B., E.T.), Milan, Italy
Received June 17, 2004; accepted August 6, 2004.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
1, and interleukin-1, compared with vehicle-treated SHRSP. Urinary excretion of acute-phase proteins increased in the latter but remained negligible in the drug-treated animals. Furthermore, valsartan exerted protective effects also when given after established proteinuria. In SHRSP, blockade of AT1 receptor with valsartan prevents the development of proteinuria, delays the appearance of brain damage, preserves renal structure, and increases survival under stressful conditions. Valsartan exerts its beneficial effects independently of any blood pressure fall and by means of broad anti-inflammatory actions both at local and at systemic levels. These observations indicate that the administration of AT1 receptor antagonists may be useful in pathological situations in which an anti-inflammatory effect is required.
; Luft, 2002). Activation of the RAS has been recorded in animal models of kidney disorders whether hypertension is present or not (Egido, 1996). Angiotensin II (AngII), the main hormone of the RAS, has significant proinflammatory actions on the vascular wall, inducing the production of reactive oxygen species, inflammatory cytokines, and adhesion molecules (Brasier et al., 2002). Experimental evidence obtained in recent years indicate that AngII is not only a vasoactive hormone but acts directly as a cytokine and a growth factor (Sadoshima, 2000; Ruiz-Ortega et al., 2002). Infusion of AngII into rats causes the infiltration of inflammatory cells into the glomeruli and the interstitium (Ruiz-Ortega et al., 2001). AngII recruits inflammatory cells into the tissue by directly activating mononuclear cells and regulating the synthesis of adhesion molecules and chemokines, including in particular monocyte chemoattractant protein-1 (MCP-1) (Tummala et al., 1999). The recruited inflammatory cells can in turn activate the RAS and increase the generation of AngII locally, thus generating a cycle of tissue injury (Ruiz-Ortega et al., 2001). AngII exerts these inflammatory effects primarily through the angiotensin II type 1 (AT1) receptor (Nataraj et al., 1999). In vivo studies with animal models of malignant hypertension indicate that AngII type 1 receptor blockers (ARBs) prevent nephrosclerosis independently of blood pressure effects and reduce angiotensin-induced inflammation in the kidney (Hilgers et al., 2001). The spontaneously hypertensive stroke-prone rat (SHRSP) is an animal model of hypertension with very high plasma levels of AngII; the animals spontaneously develop renal damage and cerebral abnormalities (Gahnem et al., 1994). We have recently shown that the appearance of cerebral abnormalities detected by MRI is preceded by a systemic inflammation characterized by the accumulation in serum and urine of acute-phase proteins, particularly thiostatin, which is the most usual marker of an inflammatory response in the rat (Sironi et al., 2001; Guerrini et al., 2002). Inflammatory processes play a pivotal role in the pathological events occurring in salt-loaded SHRSP (Marks et al., 2001; Sironi et al., 2001, 2003). This model may therefore be a useful experimental tool to explore the anti-inflammatory properties of drugs, especially those acting on the RAS. The present report focuses on the effects of valsartan, an AT1-subtype angiotensin receptor antagonist, on the pathological phenomena occurring in SHRSP with particular attention paid to the modulation of inflammatory events. |
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
40 mg/day) predicts the appearance of brain abnormalities in SHRSP (Blezer et al., 1998; Guerrini et al., 2002) and was used to schedule the frequency of MRI investigations. The SHRSP underwent MRI every week until 24-h proteinuria exceeded 40 mg/day, then every other day until brain damage was observed and every day for 3 days afterwards. Animal treatment lasted up to 100 days. Proteomic Studies. Urine proteins were concentrated by trichloroacetic acid-acetone precipitation. One-dimensional electrophoresis was run on urine proteins in the presence of SDS, without sample reduction, in a discontinuous buffer system (Laemmli 680–685) on polyacrylamide gradients 4 to 20% T. The sample load was 3.75 µg per lane. Two-dimensional electrophoresis was run according to the manufacturer's protocol (Protean IEF cell; Bio-Rad, Hercules, CA). IPG ready strips, 11 cm, pH 3 to 10 nonlinear gradient (Bio-Rad), were actively rehydrated at 50 V for 24 h. Proteins (100 µg), dissolved in a buffer containing 8 M urea, 2 M thiourea, 4% CHAPS, 1% DTT, 20 mM Tris, and 2% carrier ampholytes, were loaded on the cathode using the cup loading tray for Protean IEF cell (Bio-Rad) and focused for a total of 20 kV hours. After focusing, the strips were first equilibrated for 15 min with a solution containing 50 mM Tris-HCl, 6 M urea, 30% v/v glycerol, 2% SDS, and 2% DTT and with the same buffer containing 4.5% iodoacetamide instead of DTT. The focused proteins were then fractionated according to size by SDS-polyacrylamide gel electrophoresis on 7 to 17% polyacrylamide gradients and stained by a silver-staining method. The protein patterns were digitalized with a scanner and compared with previously reported maps.
MRI Evaluation of Brain Damage. The rats were anesthetized with 2% isofluorane in 70% N2-30% O2, and placed inside a Bruker AMX3 with a micro-imaging accessory. After a sagittal scout image, sixteen contiguous 1-mm-thick slices were analyzed caudally to the olfactory bulb using a field of view of 4 x 4 cm2. A turbo spin echo sequence was used with 16 echoes per excitation, 10 ms of interecho time, 85 ms of equivalent echo time, and 4 s of repetition time. The images were 128 x 128 points (zero filled to 256 x 256); eight images were averaged in 8 h 30 s. The occurrence of lesions was identified as the presence of areas of high signal intensity on T2-weighted MRI.
Histopathology. For the histological examination of brain and kidney, rats (n = 6) from each experimental group were sacrificed 3 and 6 weeks after starting the treatment and when brain abnormalities were first detected in the control group. To monitor the initial situation, tissues were prepared from a group of five rats aged 6 weeks. The removed kidneys and brains were fixed in Carnoy reagent (Merck, Darmstadt, Germany) and embedded in Paraplast (Sigma-Aldrich, St. Louis, MO), then 5-µm coronal sections were stained with hematoxylin/eosin and examined by light microscopy. Vascular changes in the kidney slices were evaluated assigning a score as follows: 0, absent; 1, initial deposition of hyaline material; 2, mild to moderate thickening of the vascular wall; 3, severe lesion with occlusion of vascular lumens. Tubular cast and tubular atrophy were assigned a score separately and the score values were combined (cast 0, absent; 1, isolated tubular cast in the cortex <5%; 2, large cast in less than 50% of the fields; 3, prominent cast formation; atrophy 0, absent; 1, mild; 2, moderate; 3, severe). The evaluations were performed on at least five sections of kidney from each animal by a pathologist who was unaware of the nature of the experimental groups.
Immunohistochemistry of Kidney. For immunohistochemical studies, paraffin-embedded slides from kidney were dewaxed in xylene and dehydrated. Endogenous peroxidase was blocked by adding 1% H2O2 in 50% methanol. Nonspecific binding sites were saturated with goat serum. The sections were incubated overnight at 4°C with the primary antibody anti-ED1 (1:100; Serotec, Oxford, UK), then with biotinylated secondary antibodies and streptavidin peroxidase (LSAB2 kit; DakoCytomation Denmark A/S, Glostrup, Denmark). Horseradish peroxidase was detected with H2O2 and diaminobenzidine (Sigma-Aldrich). Intraglomerular ED1-positive cells were counted in all glomeruli of a given kidney section (100 to 300 glomeruli, no selection) and were expressed as cells per glomerular section. Interstitial ED1-positive cells were assessed by a semiquantitative evaluation assigning a score as follows: 0, no staining; 1, few isolated positive cells; 2, moderate staining; 3, strong staining.
Analysis of mRNA for MCP-1, Transforming Growth Factor-1 (TGF-1), and Interleukin-1 (IL-1). Total RNA was prepared by guanidium thiocyanate denaturation from frozen kidney collected from vehicle- and valsartan (10 mg/kg/day)-treated rats sacrificed after 6 weeks of dietary treatment. The expression of MCP-1, TGF-1, and IL-1 was measured by semi-quantitative RT-PCR (Balduini et al., 2003). GAPDH was amplified as a standard. The RT-PCR products were separated on 1.5% agarose gel and visualized by means of ethidium bromide. The intensity of each band was quantified using the NIH Image software and expressed in arbitrary units. The densities of the MCP-1, TGF-1, and IL-1 bands were normalized using the corresponding GAPDH signal.
Statistical Analysis. Data are expressed as mean ± S.D. Data were analyzed using a nonparametric Kruskal-Wallis test. Differences between groups, concerning physiological parameters, were computed by analysis of variance for repeated measurements, followed by Bonferroni's post hoc test. p < 0.05 was taken as statistically significant.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
SHRSP exposed to salt loading developed a severe hypertension not significantly affected by the treatment with either tested dose of valsartan (1 or 10 mg/kg/day; Fig. 1B). Interestingly, blood pressure remained unaffected also when control animals received valsartan starting on week 6 (Fig. 6).
|
Valsartan Delayed the Appearance of Brain Abnormalities. The SHRSP in the salt-loaded control group developed cerebral lesions, as visualized by MRI, 40 ± 5 days from the beginning of the treatment (Fig. 2B). Treatment with valsartan (1 or 10 mg/kg/day) significantly delayed the appearance of brain damage (Fig. 2A) to 61 ± 3 days (p < 0.01 versus vehicle-treated rats) and 70 (p < 0.01 versus group 1) days. Of the animals on the higher dose, 80% showed no brain damage during the 100-day test period until they were sacrificed. Affected rats died 7 to 10 days after brain abnormalities appeared, whatever the treatment. In animals sacrificed at first MRI detection of brain abnormalities, no difference was found between vehicle- and drug-treated rats in the magnitude of the brain damage revealed by MRI or of the tissue lesions detected by histology (Fig. 2B).
|
Effects of Valsartan on Protein Excretion. The animals given vehicle progressively increased their daily protein loss. After 5 to 6 weeks of salt loading, 24-h proteinuria increased rapidly and linearly to average 282 ± 22 mg/day. This is the time when brain abnormalities also appeared (Fig. 2B). In rats treated with valsartan at 1 mg/kg/day, the proteinuria remained lower than in control rats but again quickly increased just before the appearance of brain abnormalities (Fig. 1C: p < 0.01 vehicle-treated rats versus 10 mg/kg/day valsartan at weeks 7 and 8; p < 0.01 1 mg/kg/day valsartan versus 10 mg/kg/day valsartan-treated rats at weeks 10 and 11). Development of proteinuria was completely prevented by valsartan at 10 mg/kg/day, and protein excretion averaged 79 ± 16 mg/day after 12 weeks of this treatment (Fig. 1C). In the urine of salt-loaded SHRSP that received vehicle only, the qualitative protein composition also changed over time; there was an accumulation of acute-phase proteins, in particular thiostatin (or 
1-major acute-phase protein; 1-MAP), as assessed by two-dimensional electrophoresis. Figure 3, panel A, shows a representative two-dimensional electrophoresis of urine from a control rat after 6 weeks of dietary treatment, compared with that from a rat treated with valsartan at 10 mg/kg/day. High concentrations, specifically of thiostatin, were observed in the urine of untreated rats whereas it was hardly detectable in the urine of drug-treated SHRSP. The mixture of proteins excreted by untreated SHRSP and by those given valsartan was compared on one-dimensional gels (Fig. 3, panel B). Treatment with either dose of valsartan delayed the appearance of high molecular weight proteins, mainly albumin and transferrin, at the expense of major urinary protein (Fig. 3).
|
Effects of Valsartan on the Progression of Renal Disorder. Kidneys from control animals sacrificed at different times during salt loading exhibited progressive fibrocellular proliferative lesions, particularly in the glomeruli and arteries. After 6 weeks of salt loading, the immunohistochemical analysis showed a massive inflammatory cell infiltration around the arteries and the renal tubules. Most of these infiltrating inflammatory cells were positive for ED-1, a marker of macrophages derived from circulating monocytes. Valsartan treatment strongly reduced (lower dose) or fully prevented (higher dose) the renal lesion and the infiltration of inflammatory cells (Fig. 4). Table 1 reports the morphologic evaluations and a quantification of ED-1 accumulation in the kidney of rats treated for 6 weeks with vehicle or valsartan.
|
|
Expression of MCP-1, TGF-1, and IL-1 mRNA in the Kidneys. Figure 5 shows the expression of the genes of chemokines in kidneys of rats treated with vehicle or 10 mg/kg/day valsartan and sacrificed after 6 weeks of dietary treatment. Valsartan treatment dramatically prevented mRNA accumulation for the three genes investigated. Drug treatment reduced IL-1, MCP-1, and TGF-1 mRNA to 71% (p < 0.001, n = 5), 64% (p < 0.001, n = 5), and 51% (p < 0.05, n = 5) of untreated SHRSP, respectively (Fig. 5).
|
Effects of Valsartan Treatment at Proteinuria >40 mg/day. When proteinuria reached 40 mg/day in 20 rats on the salt-loading diet, half the animals were given valsartan (10 mg/kg/day) whereas the remainder received vehicle. During drug treatment, body weight progressively increased, whereas the control rats lost weight upon approaching death. Blood pressure increased in the two groups to the same extent. Valsartan treatment stabilized proteinuria for at least 3 weeks; after this period, proteinuria increased between weeks 10 and 13 but remained lower than in controls on week 7. All the rats treated with valsartan after the rise in proteinuria survived 100 days on the salt-loading diet (Fig. 6).
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Abrahamsen et al., 2002). Similarly, clinical studies indicated that ARBs improve vascular function independently of the blood pressure-lowering effect (Klingbeil et al., 2002; Lewis, 2002; Viberti et al., 2002). Recently, it was reported that diabetes-associated atherosclerosis was improved by AT1 receptor blockade but not by calcium channel antagonism, despite a similar blood pressure reduction (Candido et al., 2004). These experimental and clinical results suggest that ARBs may beneficially affect vascular function beyond controlling blood pressure. In recent years many experimental data have suggested that the RAS participates in immune and inflammatory responses (Tummala et al., 1999; Dzau, 2001). In particular, angiotensin II, acting mainly through the AT1 receptor, regulates several NF-
B-related genes, including growth factors, cytokines, and adhesion molecules, which are involved in the pathogenesis of inflammatory lesions, vascular and kidney damage, and hypertension (Ruiz-Ortega et al., 1998; Muller et al., 2000; Dandona et al., 2003). AngII also participates in the recruitment of inflammatory cells into the site of injury via direct activation of the inflammatory cells or via regulation of adhesion molecules, cytokines, and chemokines such as MCP-1 (Tummala et al., 1999). Increased expression of TGF- accompanies the progression of renal disease, and the inhibition of its activity by a specific neutralizing antibody has been reported to prevent nephropathy (Sharma et al., 1996). In the present investigation, valsartan suppresses the up-regulation of MCP-1 and of TGF- and reduces macrophage infiltration and the progression of renal disease, independently of any effect on hypertension. Our data indicate that valsartan treatment inhibits the expression of IL-1 mRNA in the kidney. IL-1 is a immunoregulatory and proinflammatory cytokine released by various cells, including macrophages and activated mesangial cells (Dinarello, 1996). IL-1 influences by different mechanisms various cellular functions including cell proliferation, growth factors, and prostaglandin release and extracellular matrix protein production. IL-1 clearly plays an important role in the process of glomerular injury (Yu et al., 1999). Our results suggest that the beneficial effects of AT1 blockade in renal disease are due, at least in part, to a local reduction of the activation of proinflammatory and profibrotic gene transcription. SHRSP, besides exhibiting severe hypertension, renal and brain damage, develop a systemic inflammation and widespread alteration of vascular permeability characterized by the accumulation, first in serum and then in urine, of several proteins synthesized by the liver such as albumin, transferrin, transthyretin, serine protease inhibitor-3, and thiostatin, the most typical marker of an inflammatory response in the rat (Sironi et al., 2001; Guerrini et al., 2002). Systemic inflammation is the body's overall response to a local inflammation or infection. Epidemiological and experimental studies indicate that the synthesis of a number of acute-phase proteins is rapidly up-regulated in hepatocytes under the control of inflammatory mediators, in particular cytokines, originating at the site of persistent inflammation (Glurich et al., 2002; Pepys and Hirschfield, 2003). In our animal model, the accumulation of acute-phase proteins, particularly thiostatin, represents a response to an inflammatory condition that valsartan dramatically delays. Although no unequivocal evidence has been collected on the tissues or organ where inflammation first develops, our results, together with earlier reported data, show that in SHRSP kidney abnormalities, including proliferative and necrotic lesions in arterioles and glomeruli, are detectable shortly after the start of salt loading and may represent the initial insult triggering synthesis of acute-phase proteins (Blezer et al., 1999; Rocha et al., 1999). In patients with end-stage renal disease, it has been suggested that there is a complex interaction between the acute-phase inflammatory process and uremia, heart failure, malnutrition, and anemia (Bergstrom et al., 2000). Another recent report associates C-reactive protein (CRP) with renal function abnormalities in a nondiabetic population (Stuveling et al., 2003). CRP, a highly sensitive marker of systemic inflammation, is the major acute-phase protein in humans, like thiostatin is in rats. When tissue is injured or traumatized, CRP is quickly up-regulated, mainly in response to circulating mediators, in particular cytokines. Valsartan treatment has been shown to reduce CRP concentration in human plasma whereas angiotensin-converting enzyme inhibitors fail to modulate this inflammatory marker (Dandona et al., 2003; de Maat et al., 2003). In conclusion, our data indicate that in SHRSP the administration of nonhypotensive doses of valsartan retards renal damage and systemic inflammation. Furthermore, the beneficial effects obtained in SHRSP by the delayed administration of valsartan (see Fig. 6) indicate that this drug is able to reverse the ongoing pathological events in salt-loaded SHRSP. Valsartan exerts its beneficial effects by means of a broad anti-inflammatory action at the local level, reducing macrophage infiltration and expression of MCP-1, TGF-1, and IL-1 mRNA in the kidney, and at the systemic level as indicated by the reduced excretion of acute-phase proteins in the urine of salt-loaded animals. These observations indicate that the administration of an angiotensin II type 1 receptor antagonist may be useful in pathological situations in which an anti-inflammatory effect is required. |
Footnotes |
|---|
ABBREVIATIONS: RAS, renin-angiotensin system; AngII, angiotensin II; MCP-1, monocyte chemoattractant protein-1; AT1 receptor, angiotensin II type 1 receptor; ARB, AngII type 1 receptor blocker; SHRSP, spontaneously hypertensive stroke-prone rats; MRI, magnetic resonance imaging; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; TGF, transforming growth factor; IL, interleukin; RT-PCR, reverse transcription-polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CRP, C-reactive protein.
Address correspondence to: Luigi Sironi, Dipartimento di Scienze Farmacologiche, Università degli Studi di Milano, via Balzaretti 9, I-20133 Milano, Italy. E-mail: luigi.sironi{at}unimi.it
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Abrahamsen CT, Barone FC, Campbell WCJ, Nelson AH, Contino LC, Pullen MA, Grygielko ET, Edwards RM, Laping NJ, and Brooks DP (2002) The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension. J Pharmacol Exp Ther 301: 21–28.
Balduini W, Mazzoni E, Carloni S, De Simoni MG, Perego C, Sironi L, and Cimino M (2003) Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction and does not affect endothelial nitric oxide synthase expression. Stroke 34: 2007–2012.
Barone FC, Nelson AH, Ohlstein EH, Willette RN, Sealey JE, Laragh JH, Campbell WCJ, and Feuerstein GZ (1996) Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 279: 948–955.
Bergstrom J, Lindholm B, Lacson E Jr, Owen W Jr, Lowrie EG, Glassock RJ, Ikizler TA, Wessels FJ, Moldawer LL, Wanner C, and Zimmermann J (2000) What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 13: 163–175.[CrossRef][Medline]
Blezer EL, Nicolay K, Goldschmeding R, Jansen GH, Koomans HA, Rabelink TJ, and Joles JA (1999) Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema and proteinuria in stroke-prone hypertensive rats. Hypertension 33: 137–144.
Blezer EL, Schurink M, Nicolay K, Bar PR, Jansen GH, Koomans HA, and Joles JA (1998) Proteinuria precedes cerebral edema in stroke-prone rats: a magnetic resonance imaging study. Stroke 29: 167–174.
Brasier AR, Recinos A 3rd, and Eledrisi MS (2002) Vascular inflammation and renin-angiotensin system. Arterioscler Thromb Vasc Biol 22: 1257–1266.
Candido R, Allen TJ, Lassila M, Cao Z, Thallas V, Cooper ME, and Jandeleit-Dahm KA (2004) Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109: 1536–1542.
Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, and Garg R (2003) Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J Clin Endocrinol Metab 88: 4496–4501.
de Maat MP, Kluft C, Gram J, and Jespersen J (2003) Angiotensin-converting enzyme inhibitor trandolapril does not affect C-reactive protein levels in myocardial infarction patients. Circulation 108: e113.
Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87: 2095–2147.
Dzau VJ (2001) Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37: 1047–1052.
Egido J (1996) Vasoactive hormones and renal sclerosis (Nephrology Forum). Kidney Int 49: 478–597.
Gahnem F, von Lutterotti N, Camargo MJ, Laragh JH, and Sealey JE (1994) Angiotensinogen dependency of blood pressure in two high-renin hypertensive rat models. Am J Hypertens 10: 899–904.[CrossRef]
Glurich I, Grossi S, Albini B, Ho A, Shah R, Zeid M, Baumann H, Genco RJ, and De Nardin E (2002) Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin Diagn Lab Immunol 9: 425–432.
Guerrini U, Sironi L, Tremoli E, Cimino M, Pollo B, Calvio AM, Paoletti R, and Asdente M (2002) New insights into brain damage in stroke-prone rats: a nuclear magnetic imaging study. Stroke 33: 825–830.
Hilgers KF, Hartner A, Porst M, Veelken R, and Mann JFE (2001) Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension. Relation to kidney inflammation. Circulation 104: 1436–1440.
Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, and Schmieder RE (2002) AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. J Hypertens 20: 2423–2428.[CrossRef][Medline]
Lewis EJ (2002) The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens 10: 123S–128S.
Luft FC (2002) Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens 11: 59–66.[CrossRef][Medline]
Marks L, Carswell HV, Peters EE, Graham DI, Patterson J, Dominiczak AF, and Macrae IM (2001) Characterization of the microglial response to cerebral ischemia in the stroke-prone spontaneously hypertensive rat. Hypertension 38: 116–122.
Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, and Luft FC (2000) NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 35: 193–201.
Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, and Coffman TM (1999) Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Investig 104: 1693–1701.[Medline]
Pepys MB and Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Investig 111: 1805–1812.[CrossRef][Medline]
Rocha R, Chander PN, Zuckerman A, and Stier CT Jr (1999) Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232–237.
Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, and Egido J (1998) Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161: 430–439.
Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, and Egido J (2001) Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321–329.[CrossRef][Medline]
Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, and Egido J (2002) Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 82: 12–22.
Sadoshima J (2000) Cytokine actions of angiotensin II. Circ Res 86: 1187–1199.
Sharma K, Jin Y, Guo J, and Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522–530.[Abstract]
Sironi L, Calvio AM, Bellosta S, Lodetti B, Guerrini U, Monetti M, Tremoli E, and Mussoni L (2003) Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke. Brain Res 974: 184–192.[CrossRef][Medline]
Sironi L, Tremoli E, Miller I, Guerrini U, Calvio AM, Eberini I, Gemeiner M, Asdente M, Paoletti R, and Gianazza E (2001) Acute-phase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics. Stroke 32: 753–760.
Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, and De Zeeuw D (2003) C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 63: 654–661.[CrossRef][Medline]
Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, and Medford RM (1999) Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the reninangiotensin system and atherosclerosis. Circulation 100: 1223–1229.
Viberti G, Wheeldon NM, and MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106: 672–678.
Yu XQ, Fan JM, Nikolic-Paterson DJ, Yang N, Mu W, Pichler R, Johnson RJ, Atkins RC, and Lan HY (1999) IL-1 up-regulates osteopontin expression in experimental crescentic glomerulonephritis in the rat. Am J Pathol 154: 833–841.
This article has been cited by other articles:
|
|
 |
|
  G. T. Cicila, E. E. Morgan, S. J. Lee, P. Farms, S. Yerga-Woolwine, E. J. Toland, R. S. Ramdath, K. Gopalakrishnan, K. Bohman, A. L. Nestor-Kalinoski, et al. Epistatic Genetic Determinants of Blood Pressure and Mortality in a Salt-Sensitive Hypertension Model Hypertension, April 1, 2009; 53(4): 725 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ochiai, Y.-Q. Liang, M. Serizawa, and N. Kato Dynamic changes of the renin-angiotensin and associated systems in the rat after pharmacological and dietary interventions in vivo Physiol Genomics, November 12, 2008; 35(3): 330 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Li, Y. Doerffel, B. Hocher, and T. Unger Inflammation in the genesis of hypertension and its complications the role of angiotensin II Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3107 - 3109. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Graciano, C. R. Mouton, M. E. Patterson, D. M. Seth, J. J. Mullins, and K. D. Mitchell Renal vascular and tubulointerstitial inflammation and proliferation in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension Am J Physiol Renal Physiol, June 1, 2007; 292(6): F1858 - F1866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rodriguez-Iturbe and R. J. Johnson Role of inflammatory cells in the kidney in the induction and maintenance of hypertension Nephrol. Dial. Transplant., February 1, 2006; 21(2): 260 - 263. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Rodriguez-Iturbe, A. Ferrebuz, V. Vanegas, Y. Quiroz, S. Mezzano, and N. D. Vaziri Early and Sustained Inhibition of Nuclear Factor-{kappa}B Prevents Hypertension in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
), treated with 1 mg/kg/day valsartan (
), or treated with 10 mg/kg/day valsartan 
(*, p < 0.05 and **, p < 0.01 versus 10 mg/kg/day treated rats).
